+Vote!
Public Blog (Free subscription) | yesterday
Drugmaker GlaxoSmithKline has petitioned the FDA to classify weight loss claims for dietary supplements as disease claims. Many say that this is nothing more than an attempt by the makers of alli, an over-the-counter weight loss drug, to quash competition from the supplement weight loss industry. It is yet another instance of a pharmaceutical giant using its considerable monetary, legal and political...
+Vote!
New York Times (Free subscription) | yesterday
The company said it would resubmit its application for Multaq based on results from a study showing that the drug reduced both hospitalization and death in patients with atrial fibrillation.
+Vote!
Financial Time (Free subscription) | 8 hours ago
The Islamic principles of a generic drugs company have provided it with an unexpected marketing advantage, following the discovery of contaminants in a leading...
+Vote!
Tampa Bay Online (Free subscription) | 6 hours ago
Health regulators warned again Friday that Roche and Novartis drugs prescribed to organ transplant patients can cause miscarriages and birth defects when used by pregnant women.
+Vote!
Reuters UK (Free subscription) | 12 hours ago
WASHINGTON (Reuters) - An experimental drug from Swiss drugmaker Novartis slowed the progression of kidney cancer in patients whose tumors returned after initial chemotherapy, researchers reported on Friday.
+Vote!
Reuters (Free subscription) | 12 hours ago
WASHINGTON (Reuters) - An experimental drug from Swiss drugmaker Novartis slowed the progression of kidney cancer in patients whose tumors returned after initial chemotherapy, researchers reported on Friday.
+Vote!
The Washington Times (Free subscription) | 12 hours ago
Health regulators warned again today that Roche and Novartis drugs prescribed to organ transplant...
+Vote!
Orange Book Blog (Free subscription) | yesterday
The Institute for International Research will be holding its 9th annual "Generic Drugs Summit," June 18-20 in Washington, D.C. According to IIR, this is "the leading independent forum addressing business and legal concerns impacting the generics marketplace. This event attracts...
+Vote!
Law Blog - WSJ.com (Free subscription) | yesterday
Health regulators warned again that Roche and Novartis drugs prescribed to organ transplant patients can cause miscarriages and birth defects when used by pregnant women.
+Vote!
USA Today (Free subscription) | yesterday
Health regulators reiterated their warning Friday that organ transplant drugs from Roche and Novartis can cause miscarriages ...
+Vote!
San Fransisco Chronicle (Free subscription) | yesterday
Health regulators reiterated their warning Friday that organ transplant drugs from Roche and Novartis can cause miscarriages and birth defects when used by pregnant women. The Food and Drug Administration previously said it received reports of miscarriages...
+Vote!
PharmaGossip (Free subscription) | yesterday
Up to 32,000 Big Pharma jobs could be axed in France over the next few years, according to a study commissioned by Leem, the French pharmaceutical industry body. The Arthur D. Little study names five major factors threatening the pharmaceutical model: pricing pressures; generics; changing areas of growth, the break up of the traditional value chain as a result of the rise of biotechnology;...
+Vote!
Seeking Alpha (Free subscription) | yesterday
Eben Tessari submits: German-based MediGene hit a 52 week high yesterday on rumors that they are in discussions with the drug giant Pfizer (PFE). MediGene is just the latest of half a dozen companies mentioned in the same sentence as Pfizer in the last few months (others include Biogen, Shire, King and NicOx). In the past year, many analysts have urged Pfizer to consider buying a midsized drug maker...
+Vote!
PR News Wire (Free subscription) | yesterday
ROCKVILLE, Md., May 16 /PRNewswire-FirstCall/ -- Human Genome Sciences,
Inc. (Nasdaq: ) announced today that its presentation at the 2008 Citi
Investment Research Global Healthcare Conference will be webcast and may be
accessed at
(Logo: )
A member of Human Genome Sciences' senior management team will present
a corporate overview on Wednesday, May 21, 2008 at 3:00 pm Eastern Time.
Investors...
1Vote!
nitesh | 01/07/2008
The global pharmaceutical industry is at the cross roads. With many of the blockbuster drugs getting off-patented and with increasing R&D costs, it's hard by the companies to maintain their bottom-line and remain unaffected. They have found recourse to outsourcing some of their research and manufacturing activities and saving cost in the process. This has led to the growth of contract research and...
+Vote!
nitesh | 01/07/2008
Pharmaceutical business is a blend of commerce and public service. Globally, the pharmaceutical industry grew at a compounded annual growth rate (CAGR) of 9.1 per cent in the last 23 years- powered by a string of innovative blockbusters. It is an industry characterized by huge investments in drug discovery and development. In the recent past, falling research productivity triggered off a series of...
2Vote!
traderthoughts.com | 12/27/2007
Biologic products grew at an average clip of 17% over the past two years, a growth higher than any other sub-sector within the pharmaceutical industry. There are many biologics in the approval pipeline and it has been projected that 50% of drugs approved for the marketplace in 2010 will be the result of biotechnology. Biologic medicines, manufactured from complex living cells, provide some of the
